Calla Lily Clinical Care secures £1m from the National Institute for Health and Care Research to advance clinical trials
The funding will support the development of the Callavid drug-device combination for threatened miscarriage.
Calla Lily Clinical Care is a certified B-Corporation developing a novel drug-device combination to improve treatment for threatened miscarriage.
Calla Lily Clinical Care has secured £1m in funding from the National Institute for Health and Care Research to advance its flagship Callavid drug-device combination through clinical trials.
The investment will support a phased clinical trial process, beginning with a usability study this month and a feasibility study later in 2025, followed by bioequivalence trials and regulatory applications.
The company seeks to replace traditional leaky pessaries with a tampon-shaped device that ensures better progesterone absorption and reduces patient anxiety.
From the founder
"this new product will be extremely welcomed by miscarriage patients. Pessary leakage is a recurring issue amongst my patients, causing acute anxiety and significant inconvenience during a very difficult time."
Siobhan Quenby
Miscarriage specialist at Calla Lily Clinical Care
Investor perspective
"the NIHR's mission is to enable world-leading research that improves people's health and wellbeing. The innovation being pioneered by the team at Calla Lily Clinical Care aligns exactly with this vision."
Michael Lewis
Scientific Director for Innovation, National Institute for Health and Care Research
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Calla Lily Clinical Care
Developing advanced drug delivery systems for women's healthcare.